Patents by Inventor Roland Joseph Billedeau

Roland Joseph Billedeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20240132533
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: November 1, 2023
    Publication date: April 25, 2024
    Inventors: Lijing CHEN, Roland Joseph BILLEDEAU, Jim LI
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11858957
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: January 2, 2024
    Assignee: ANTENGENT THERAPEUTICS LIMITED
    Inventors: Lijing Chen, Roland Joseph Billedeau, Jim Li
  • ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230022922
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: June 28, 2021
    Publication date: January 26, 2023
    Inventors: Lijing Chen, Roland Joseph Billedeau, Jim Li
  • ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220363709
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: June 18, 2020
    Publication date: November 17, 2022
    Inventors: Lijing CHEN, Roland Joseph BILLEDEAU, Jim LI, Timothy Friend STANTON
  • Ectonucleotidase inhibitors and methods of use thereof
    Patent number: 11078228
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: August 3, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Lijing Chen, Roland Joseph Billedeau, Jim Li
  • ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20190389899
    Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Inventors: Lijing Chen, Roland Joseph Billedeau, Jin Li
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 8940741
    Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: January 27, 2015
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 8729078
    Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: May 20, 2014
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roland Joseph Billedeau, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou, Timothy D. Owens, Yimin Qian, Sung-Sau So, Kshitij C. Thakkar, Jutta Wanner, Omar Jose Morales
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 8481540
    Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: July 9, 2013
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
  • Tricyclic inhibitors of JAK
    Patent number: 8361962
    Abstract: The present invention relates to the use of novel compounds of Formulae I-II, wherein the variables R, X1, X2, X3, Y1, Y2, Y3, Z1, and Z2 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: January 29, 2013
    Assignee: Roche Palo Alto LLC
    Inventor: Roland Joseph Billedeau
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20120295885
    Abstract: This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Application
    Filed: May 16, 2012
    Publication date: November 22, 2012
    Inventors: Roland Joseph Billedeau, Rama K. Kondru, Francisco Javier Lopez-Tapia, Yan Lou, Timothy D. Owens, Yimin Qian, Sung-Sau So, Kshitij C. Thakkar, Jutta Wanner
  • Inhibitors of Bruton's Tyrosine Kinase
    Publication number: 20120040949
    Abstract: This application discloses 6-(2-Hydroxymethyl-phenyl)-2-methyl-2H-pyridazin-3-one derivatives according to generic Formula I: wherein, variables X, R, and Y4, are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation, such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
    Type: Application
    Filed: August 11, 2011
    Publication date: February 16, 2012
    Inventors: Steven Joseph Berthel, Roland Joseph Billedeau, Christine E. Brotherton-Pleiss, Fariborz Firooznia, Stephen Deems Gabriel, Xiaochun Han, Ramona Hilgenkamp, Saul Jaime-Figueroa, Buelent Kocer, Francisco Javier Lopez-Tapia, Yan Lou, Lucja Orzechowski, Timothy D. Owens, Jenny Tan, Peter Michael Wovkulich
  • Heterocyclic antiviral compounds
    Patent number: 8063028
    Abstract: Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: November 22, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Roland Joseph Billedeau, Zachary Kevin Sweeney
  • TRICYCLIC INHIBITORS OF JAK
    Publication number: 20110021425
    Abstract: The present invention relates to the use of novel compounds of Formulae I-II, wherein the variables R, X1, X2, X3, Y1, Y2, Y3, Z1, and Z2 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Application
    Filed: June 29, 2010
    Publication date: January 27, 2011
    Inventor: Roland Joseph Billedeau
  • Inhibitors of HIV-1 reverse transcriptase
    Publication number: 20100056535
    Abstract: The present invention provides compounds for treating or preventing an HIV infection, or treating AIDS or ARC comprising administering a compound according to Formulae I and II wherein Q, R1, R2, and R3 are defined as described herein.
    Type: Application
    Filed: September 4, 2009
    Publication date: March 4, 2010
    Inventors: Nidhi Arora, Roland Joseph Billedeau, Joshua Kennedy-Smith, Weiling Liang, Ralf Roetz, Zachary Kevin Sweeney
  • Substituted pyrazolo{3,4-D}pyrimidines as p38 map kinase inhibitors
    Patent number: 7566708
    Abstract: Compounds effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: July 28, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Nidhi Arora, Roland Joseph Billedeau, Nolan James Dewdney, Tobias Gabriel, David Michael Goldstein, Counde O'Yang, Michael Soth, Teresa Alejandra Trejo-Martin
  • Substituted pyrazolo[3,4-D]pyrimidines as p38 map kinase inhibitors
    Patent number: 7563799
    Abstract: Compounds of the formula Ia or Ib: wherein X and Y are N or one of X and Y is N and the other is CRg, and A, D, E, G, W, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the subject compounds and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: July 21, 2009
    Assignee: Roche Palo Alto LLC
    Inventors: Roland Joseph Billedeau, Nolan James Dewdney, Tobias Gabriel
  • HETEROCYCLIC ANTIVIRAL COMPOUNDS
    Publication number: 20090170856
    Abstract: Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.
    Type: Application
    Filed: December 22, 2008
    Publication date: July 2, 2009
    Inventors: Roland Joseph Billedeau, Zachary Kevin Sweeney
  • Non-nucleoside reverse transcriptase inhibitors
    Publication number: 20080293664
    Abstract: Compounds of formula I, wherein R1, R2, R3, R4, Ra, X, X1, and Y are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.
    Type: Application
    Filed: April 8, 2008
    Publication date: November 27, 2008
    Inventors: Roland Joseph Billedeau, Wylie Solang Palmer, Zachary Kevin Sweeney, Jeffrey Wu
  • Substituted pyrazolo [3,4-d] pyrimidines and methods of using the same
    Patent number: 7452880
    Abstract: Compounds of the formula I: where A, B, X, Y, Z, k, R1, R2 and R3 are those defined herein, and compositions comprising the same. The present invention also provides methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a patient.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: November 18, 2008
    Inventors: Nidhi Arora, Roland Joseph Billedeau, Nolan James Dewdney, Tobias Gabriel, David Michael Goldstein, Teresa Alejandra Trejo-Martin